AMAngelo Modica

Angelo Modica

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Angelo Modica has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Systematic, randomised atrial fibrillation screening using detailed phenotyping with a risk-prediction model combined with patch electrocardiogram in a Swedish population aged 65 years or older: The CONSIDERING-AF trial

    by Emelie Rakai, Farzaneh Etminani, Ninia Younan, Anton Andersson, Maria Andersson, Torbjörn Vik, Stefan Kunkel, Anna Sundin, Johan Holm, Angelo Modica, et al.

    Background and aims: Atrial fibrillation (AF), often asymptomatic and underdiagnosed, is an independent risk factor for ischemic stroke. A knowledge gap remains regarding the optimal target population, and method to use for AF screening. We aimed to test whether screening for AF using a machine learning-based risk-prediction model (RPM) and 14-day continuous patch electrocardiogram (ECG) (Philips ePatch) in high-risk individuals ≥65 years is more effective than standard care. Methods: Individuals ≥65 years were assigned to general or RPM cohort. The general cohort was randomised to control or invitation. In the RPM cohort, high-risk individuals, identified by RPM, were randomised to control or invitation. The primary outcome was six-month AF incidence, analysed as intention-to-invite, comparing RPM + invitation with general + control. Results: Of 2,960 randomised individuals, participation was 43% (632/1480) in invitation arms. AF incidence was higher in RPM + invitation than in general + control arm (3.8%, 28/740 versus 0.7%, 5/740; p<0.001), yielding a risk ratio of 5.6, (95% confidence interval [2.2, 14.4]), and a number needed to invite of 32. AF was more often detected in RPM + invitation than in general + invitation arm (1.1%, 8/740; p<0.001), but not more often than in RPM + control arm (2.2%, 16/740; p=0.07). No difference was found between general + invitation and general + control arms (1.1%, 8/740 versus 0.7%, 5/740; p=0.40). Conclusion: Among high-risk individuals ≥65 years, the combination of a machine learning-based risk-prediction model and long-term ECG recording was superior to standard care in identifying new AF cases.


  • Open Access

    Anticoagulation and antiplatelet strategies used in Sweden in patients with myocardial infarction and concomitant atrial fibrillation: nationwide cohort study

    by Julia Aulin, Angelo Modica, Lars Lindhagen, Joakim Alfredsson, Claes Held, Stefan James, Gorav Batra

    Background: Optimal antithrombotic therapy and its duration, whether triple therapy with dual antiplatelets plus oral anticoagulant (OAC), or dual antithrombotic therapy with an antiplatelet plus OAC, is uncertain for patients with myocardial infarction (MI) and atrial fibrillation (AF). Methods: Patients registered in SWEDEHEART (Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies) for their first MI between 2011 and 2021 with a history or new-onset AF were included (n=26 574). Linkage between SWEDEHEART and Swedish administrative health databases was performed, and pseudonymised data analysed. Results: Over time, OAC use at discharge after MI tripled from 27% in 2011 to 77% in 2021, with direct OACs (DOACs) largely replacing warfarin, predominantly in combination with a single antiplatelet. The strongest factors for initiating OAC therapy were the performance of coronary angiography (OR 1.53 (1.40–1.68)), and percutaneous coronary intervention (OR 1.49 (1.39–1.61)). However, the year of the MI was the most predictive variable associated with OAC initiation, with an OR of 9.31 (7.92–10.95) in 2021 compared with 2011. The clinical factors associated with lower likelihood of OAC initiation were dementia, liver disease, cancer and ST-elevation MI (STEMI) versus non-STEMI. Conclusions: Use of OAC has increased over the years in patients with MI and concurrent AF, primarily driven by the increased adoption of DOACs. Additionally, there has been a shift in antithrombotic combinations, with most patients in recent years receiving DOAC in combination with a single antiplatelet, reflecting the nationwide implementation of recent evidence and guidelines. However, significant variation in antithrombotic therapy strategies remains.